SrasV1, PascalFrancis, Curation, bibRecord, 000414

Synthesis of novel test compounds for antiviral chemotherapy of severe acute respiratory syndrome (SARS)

Identifieur interne : 000414 ( PascalFrancis/Curation ); précédent : 000413; suivant : 000415

Synthesis of novel test compounds for antiviral chemotherapy of severe acute respiratory syndrome (SARS)

Auteurs : Andreas J. Kesel [Allemagne]

Source :

Current medicinal chemistry [ 0929-8673 ] ; 2005.

RBID : Pascal:05-0492308

Descripteurs français

Pascal (Inist)
- Synthèse chimique, Antiviral, Chimiothérapie, Syndrome respiratoire aigu sévère, Article synthèse, Relation structure activité, Gravimétrie, Spectrométrie UV, Spectrométrie IR, Spectrométrie RMN, Corrélation hétéronucléaire, Composé cage, Orthoester, Hétérocycle azote, Protéomique, Réplication, Virus syndrome respiratoire aigu sévère, Bananine, 2,8,9-Trioxaadamantane-3,5,7-triol dérivé, Prismane dérivé, Indolo[2,3-b]quinoxaline dérivé.

English descriptors

KwdEn :
- Antiviral, Cage compound, Chemical synthesis, Chemotherapy, Gravimetric analysis, Heteronuclear correlation, Infrared spectrometry, NMR spectrometry, Nitrogen heterocycle, Orthoester, Proteomics, Replication, Review, Severe acute respiratory syndrome, Severe acute respiratory syndrome virus, Structure activity relation, Ultraviolet spectrometry.

Abstract

This contribution reviews the synthesis of a range of experimental drugs designed for and aiming at antiviral chemotherapy of severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV)-induced human disease conditions. The selection of 25 test materials includes eleven trioxa-adamantane-triols (TATs) [BN, IBNCA, ABNCA, VANBA, ethylVANBA, euBN, euVANBA, ansaBN, Ehrlich BN, [6]prismaneBN, nitrodiBN], trivially termed bananins, one trioxa-adamantan-ol (TAO) THYMOBA, one bis-bananin pi-bananin (piBN), one triazaadamantane delta-bananin (deltaBN), seven potential nucleic acid-binding drugs (XBQC, INDO, PivINDO, AZTRION, AZADO, AZOCYS, AZOGALL), one potential antiviral interferon-inducer and distant nucleoside analog diazon, one potential HIV protein Vif antagonist AZODIAZON, one folic acid-diazon condensate DIAZONOFOL, and one special nucleoside analog (fructoinosine/fructovir). Four of the eleven bananins (BN, IBNCA, VANBA, euBN) were already demonstrated to constitute effective inhibitors of SARS-CoV NSP10/nsp13 RNA/DNA helicase/NTPase protein ATPase enzymatic function. Bananin (BN) was an effective inhibitor of both SARS-CoV RNA/DNA helicase nucleic acid unwinding function and SARS-CoV (Coronaviridae, Coronavirus) RNA-viral replication in cell culture. In , at least one selected compound of the synthesized test materials represents an interesting drug candidate for treatment of SARS-CoV-induced human disease (SARS). Viewed in aspects of organic chemistry [6]prismaneBN and nitrodiBN are the first true hexaprismane derivatives synthesized, and all reported compounds are entirely new.

A01	`01`	`1`		`@0 0929-8673`
A03		`1`		`@0 Curr. med. chem.`
A05				`@2 12`
A06				`@2 18`
A08	`01`	`1`	`ENG`	`@1 Synthesis of novel test compounds for antiviral chemotherapy of severe acute respiratory syndrome (SARS)`
A11	`01`	`1`		`@1 KESEL (Andreas J.)`
A14	`01`			`@2 Chammiinsterstr. 47, 81827 München @3 DEU @Z 1 aut.`
A20				`@1 2095-2162`
A21				`@1 2005`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 22999 @5 354000132425740040`
A44				`@0 0000 @1 © 2005 INIST-CNRS. All rights reserved.`
A45				`@0 344 ref.`
A47	`01`	`1`		`@0 05-0492308`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Current medicinal chemistry`
A66	`01`			`@0 NLD`
C01	`01`		`ENG`	@0 This contribution reviews the synthesis of a range of experimental drugs designed for and aiming at antiviral chemotherapy of severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV)-induced human disease conditions. The selection of 25 test materials includes eleven trioxa-adamantane-triols (TATs) [BN, IBNCA, ABNCA, VANBA, ethylVANBA, euBN, euVANBA, ansaBN, Ehrlich BN, [6]prismaneBN, nitrodiBN], trivially termed bananins, one trioxa-adamantan-ol (TAO) THYMOBA, one bis-bananin pi-bananin (piBN), one triazaadamantane delta-bananin (deltaBN), seven potential nucleic acid-binding drugs (XBQC, INDO, PivINDO, AZTRION, AZADO, AZOCYS, AZOGALL), one potential antiviral interferon-inducer and distant nucleoside analog diazon, one potential HIV protein Vif antagonist AZODIAZON, one folic acid-diazon condensate DIAZONOFOL, and one special nucleoside analog (fructoinosine/fructovir). Four of the eleven bananins (BN, IBNCA, VANBA, euBN) were already demonstrated to constitute effective inhibitors of SARS-CoV NSP10/nsp13 RNA/DNA helicase/NTPase protein ATPase enzymatic function. Bananin (BN) was an effective inhibitor of both SARS-CoV RNA/DNA helicase nucleic acid unwinding function and SARS-CoV (Coronaviridae, Coronavirus) RNA-viral replication in cell culture. In , at least one selected compound of the synthesized test materials represents an interesting drug candidate for treatment of SARS-CoV-induced human disease (SARS). Viewed in aspects of organic chemistry [6]prismaneBN and nitrodiBN are the first true hexaprismane derivatives synthesized, and all reported compounds are entirely new.
C02	`01`	`X`		`@0 002B02S05`
C03	`01`	`X`	`FRE`	`@0 Synthèse chimique @5 01`
C03	`01`	`X`	`ENG`	`@0 Chemical synthesis @5 01`
C03	`01`	`X`	`SPA`	`@0 Síntesis química @5 01`
C03	`02`	`X`	`FRE`	`@0 Antiviral @5 02`
C03	`02`	`X`	`ENG`	`@0 Antiviral @5 02`
C03	`02`	`X`	`SPA`	`@0 Antiviral @5 02`
C03	`03`	`X`	`FRE`	`@0 Chimiothérapie @5 03`
C03	`03`	`X`	`ENG`	`@0 Chemotherapy @5 03`
C03	`03`	`X`	`SPA`	`@0 Quimioterapia @5 03`
C03	`04`	`X`	`FRE`	`@0 Syndrome respiratoire aigu sévère @2 NM @5 04`
C03	`04`	`X`	`ENG`	`@0 Severe acute respiratory syndrome @2 NM @5 04`
C03	`04`	`X`	`SPA`	`@0 Síndrome respiratorio agudo severo @2 NM @5 04`
C03	`05`	`X`	`FRE`	`@0 Article synthèse @5 05`
C03	`05`	`X`	`ENG`	`@0 Review @5 05`
C03	`05`	`X`	`SPA`	`@0 Artículo síntesis @5 05`
C03	`06`	`X`	`FRE`	`@0 Relation structure activité @5 06`
C03	`06`	`X`	`ENG`	`@0 Structure activity relation @5 06`
C03	`06`	`X`	`SPA`	`@0 Relación estructura actividad @5 06`
C03	`07`	`X`	`FRE`	`@0 Gravimétrie @5 07`
C03	`07`	`X`	`ENG`	`@0 Gravimetric analysis @5 07`
C03	`07`	`X`	`SPA`	`@0 Gravimetría @5 07`
C03	`08`	`X`	`FRE`	`@0 Spectrométrie UV @5 08`
C03	`08`	`X`	`ENG`	`@0 Ultraviolet spectrometry @5 08`
C03	`08`	`X`	`SPA`	`@0 Espectrometría UV @5 08`
C03	`09`	`X`	`FRE`	`@0 Spectrométrie IR @5 09`
C03	`09`	`X`	`ENG`	`@0 Infrared spectrometry @5 09`
C03	`09`	`X`	`SPA`	`@0 Espectrometría IR @5 09`
C03	`10`	`X`	`FRE`	`@0 Spectrométrie RMN @5 10`
C03	`10`	`X`	`ENG`	`@0 NMR spectrometry @5 10`
C03	`10`	`X`	`SPA`	`@0 Espectrometría RMN @5 10`
C03	`11`	`X`	`FRE`	`@0 Corrélation hétéronucléaire @5 11`
C03	`11`	`X`	`ENG`	`@0 Heteronuclear correlation @5 11`
C03	`11`	`X`	`SPA`	`@0 Correlación heteronuclear @5 11`
C03	`12`	`X`	`FRE`	`@0 Composé cage @5 12`
C03	`12`	`X`	`ENG`	`@0 Cage compound @5 12`
C03	`12`	`X`	`SPA`	`@0 Compuesto jaula @5 12`
C03	`13`	`X`	`FRE`	`@0 Orthoester @5 13`
C03	`13`	`X`	`ENG`	`@0 Orthoester @5 13`
C03	`13`	`X`	`SPA`	`@0 Ortoester @5 13`
C03	`14`	`X`	`FRE`	`@0 Hétérocycle azote @5 14`
C03	`14`	`X`	`ENG`	`@0 Nitrogen heterocycle @5 14`
C03	`14`	`X`	`SPA`	`@0 Heterociclo nitrógeno @5 14`
C03	`15`	`X`	`FRE`	`@0 Protéomique @5 15`
C03	`15`	`X`	`ENG`	`@0 Proteomics @5 15`
C03	`15`	`X`	`SPA`	`@0 Proteómica @5 15`
C03	`16`	`X`	`FRE`	`@0 Réplication @5 16`
C03	`16`	`X`	`ENG`	`@0 Replication @5 16`
C03	`16`	`X`	`SPA`	`@0 Replicación @5 16`
C03	`17`	`X`	`FRE`	`@0 Virus syndrome respiratoire aigu sévère @2 NW @5 17`
C03	`17`	`X`	`ENG`	`@0 Severe acute respiratory syndrome virus @2 NW @5 17`
C03	`17`	`X`	`SPA`	`@0 Severe acute respiratory syndrome virus @2 NW @5 17`
C03	`18`	`X`	`FRE`	`@0 Bananine @2 NK @4 INC @5 76`
C03	`19`	`X`	`FRE`	`@0 2,8,9-Trioxaadamantane-3,5,7-triol dérivé @2 NK @4 INC @5 77`
C03	`20`	`X`	`FRE`	`@0 Prismane dérivé @2 NK @4 INC @5 78`
C03	`21`	`X`	`FRE`	`@0 Indolo[2,3-b]quinoxaline dérivé @2 NK @4 INC @5 79`
C07	`01`	`X`	`FRE`	`@0 Virose`
C07	`01`	`X`	`ENG`	`@0 Viral disease`
C07	`01`	`X`	`SPA`	`@0 Virosis`
C07	`02`	`X`	`FRE`	`@0 Infection`
C07	`02`	`X`	`ENG`	`@0 Infection`
C07	`02`	`X`	`SPA`	`@0 Infección`
C07	`03`	`X`	`FRE`	`@0 Coronavirus @2 NW`
C07	`03`	`X`	`ENG`	`@0 Coronavirus @2 NW`
C07	`03`	`X`	`SPA`	`@0 Coronavirus @2 NW`
C07	`04`	`X`	`FRE`	`@0 Coronaviridae @2 NW`
C07	`04`	`X`	`ENG`	`@0 Coronaviridae @2 NW`
C07	`04`	`X`	`SPA`	`@0 Coronaviridae @2 NW`
C07	`05`	`X`	`FRE`	`@0 Nidovirales @2 NW`
C07	`05`	`X`	`ENG`	`@0 Nidovirales @2 NW`
C07	`05`	`X`	`SPA`	`@0 Nidovirales @2 NW`
C07	`06`	`X`	`FRE`	`@0 Virus @2 NW`
C07	`06`	`X`	`ENG`	`@0 Virus @2 NW`
C07	`06`	`X`	`SPA`	`@0 Virus @2 NW`
C07	`07`	`X`	`FRE`	`@0 Appareil respiratoire pathologie @5 53`
C07	`07`	`X`	`ENG`	`@0 Respiratory disease @5 53`
C07	`07`	`X`	`SPA`	`@0 Aparato respiratorio patología @5 53`
N21				`@1 346`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000576

Links to Exploration step

Pascal:05-0492308

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Synthesis of novel test compounds for antiviral chemotherapy of severe acute respiratory syndrome (SARS)</title>
<author><name sortKey="Kesel, Andreas J" sort="Kesel, Andreas J" uniqKey="Kesel A" first="Andreas J." last="Kesel">Andreas J. Kesel</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s2>Chammiinsterstr. 47, 81827 München</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">05-0492308</idno>
<date when="2005">2005</date>
<idno type="stanalyst">PASCAL 05-0492308 INIST</idno>
<idno type="RBID">Pascal:05-0492308</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000576</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000414</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Synthesis of novel test compounds for antiviral chemotherapy of severe acute respiratory syndrome (SARS)</title>
<author><name sortKey="Kesel, Andreas J" sort="Kesel, Andreas J" uniqKey="Kesel A" first="Andreas J." last="Kesel">Andreas J. Kesel</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s2>Chammiinsterstr. 47, 81827 München</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Current medicinal chemistry</title>
<title level="j" type="abbreviated">Curr. med. chem.</title>
<idno type="ISSN">0929-8673</idno>
<imprint><date when="2005">2005</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Current medicinal chemistry</title>
<title level="j" type="abbreviated">Curr. med. chem.</title>
<idno type="ISSN">0929-8673</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral</term>
<term>Cage compound</term>
<term>Chemical synthesis</term>
<term>Chemotherapy</term>
<term>Gravimetric analysis</term>
<term>Heteronuclear correlation</term>
<term>Infrared spectrometry</term>
<term>NMR spectrometry</term>
<term>Nitrogen heterocycle</term>
<term>Orthoester</term>
<term>Proteomics</term>
<term>Replication</term>
<term>Review</term>
<term>Severe acute respiratory syndrome</term>
<term>Severe acute respiratory syndrome virus</term>
<term>Structure activity relation</term>
<term>Ultraviolet spectrometry</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Synthèse chimique</term>
<term>Antiviral</term>
<term>Chimiothérapie</term>
<term>Syndrome respiratoire aigu sévère</term>
<term>Article synthèse</term>
<term>Relation structure activité</term>
<term>Gravimétrie</term>
<term>Spectrométrie UV</term>
<term>Spectrométrie IR</term>
<term>Spectrométrie RMN</term>
<term>Corrélation hétéronucléaire</term>
<term>Composé cage</term>
<term>Orthoester</term>
<term>Hétérocycle azote</term>
<term>Protéomique</term>
<term>Réplication</term>
<term>Virus syndrome respiratoire aigu sévère</term>
<term>Bananine</term>
<term>2,8,9-Trioxaadamantane-3,5,7-triol dérivé</term>
<term>Prismane dérivé</term>
<term>Indolo[2,3-b]quinoxaline dérivé</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">This contribution reviews the synthesis of a range of experimental drugs designed for and aiming at antiviral chemotherapy of severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV)-induced human disease conditions. The selection of 25 test materials includes eleven trioxa-adamantane-triols (TATs) [BN, IBNCA, ABNCA, VANBA, ethylVANBA, euBN, euVANBA, ansaBN, Ehrlich BN, [6]prismaneBN, nitrodiBN], trivially termed bananins, one trioxa-adamantan-ol (TAO) THYMOBA, one bis-bananin pi-bananin (piBN), one triazaadamantane delta-bananin (deltaBN), seven potential nucleic acid-binding drugs (XBQC, INDO, PivINDO, AZTRION, AZADO, AZOCYS, AZOGALL), one potential antiviral interferon-inducer and distant nucleoside analog diazon, one potential HIV protein Vif antagonist AZODIAZON, one folic acid-diazon condensate DIAZONOFOL, and one special nucleoside analog (fructoinosine/fructovir). Four of the eleven bananins (BN, IBNCA, VANBA, euBN) were already demonstrated to constitute effective inhibitors of SARS-CoV NSP10/nsp13 RNA/DNA helicase/NTPase protein ATPase enzymatic function. Bananin (BN) was an effective inhibitor of both SARS-CoV RNA/DNA helicase nucleic acid unwinding function and SARS-CoV (Coronaviridae, Coronavirus) RNA-viral replication in cell culture. In , at least one selected compound of the synthesized test materials represents an interesting drug candidate for treatment of SARS-CoV-induced human disease (SARS). Viewed in aspects of organic chemistry [6]prismaneBN and nitrodiBN are the first true hexaprismane derivatives synthesized, and all reported compounds are entirely new.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0929-8673</s0>
</fA01>
<fA03 i2="1"><s0>Curr. med. chem.</s0>
</fA03>
<fA05><s2>12</s2>
</fA05>
<fA06><s2>18</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Synthesis of novel test compounds for antiviral chemotherapy of severe acute respiratory syndrome (SARS)</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>KESEL (Andreas J.)</s1>
</fA11>
<fA14 i1="01"><s2>Chammiinsterstr. 47, 81827 München</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA20><s1>2095-2162</s1>
</fA20>
<fA21><s1>2005</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>22999</s2>
<s5>354000132425740040</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2005 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>344 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>05-0492308</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Current medicinal chemistry</s0>
</fA64>
<fA66 i1="01"><s0>NLD</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>This contribution reviews the synthesis of a range of experimental drugs designed for and aiming at antiviral chemotherapy of severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV)-induced human disease conditions. The selection of 25 test materials includes eleven trioxa-adamantane-triols (TATs) [BN, IBNCA, ABNCA, VANBA, ethylVANBA, euBN, euVANBA, ansaBN, Ehrlich BN, [6]prismaneBN, nitrodiBN], trivially termed bananins, one trioxa-adamantan-ol (TAO) THYMOBA, one bis-bananin pi-bananin (piBN), one triazaadamantane delta-bananin (deltaBN), seven potential nucleic acid-binding drugs (XBQC, INDO, PivINDO, AZTRION, AZADO, AZOCYS, AZOGALL), one potential antiviral interferon-inducer and distant nucleoside analog diazon, one potential HIV protein Vif antagonist AZODIAZON, one folic acid-diazon condensate DIAZONOFOL, and one special nucleoside analog (fructoinosine/fructovir). Four of the eleven bananins (BN, IBNCA, VANBA, euBN) were already demonstrated to constitute effective inhibitors of SARS-CoV NSP10/nsp13 RNA/DNA helicase/NTPase protein ATPase enzymatic function. Bananin (BN) was an effective inhibitor of both SARS-CoV RNA/DNA helicase nucleic acid unwinding function and SARS-CoV (Coronaviridae, Coronavirus) RNA-viral replication in cell culture. In , at least one selected compound of the synthesized test materials represents an interesting drug candidate for treatment of SARS-CoV-induced human disease (SARS). Viewed in aspects of organic chemistry [6]prismaneBN and nitrodiBN are the first true hexaprismane derivatives synthesized, and all reported compounds are entirely new.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02S05</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Synthèse chimique</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Chemical synthesis</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Síntesis química</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Antiviral</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Antiviral</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Antiviral</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Syndrome respiratoire aigu sévère</s0>
<s2>NM</s2>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Severe acute respiratory syndrome</s0>
<s2>NM</s2>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Síndrome respiratorio agudo severo</s0>
<s2>NM</s2>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Article synthèse</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Review</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Artículo síntesis</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Relation structure activité</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Structure activity relation</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Relación estructura actividad</s0>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Gravimétrie</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Gravimetric analysis</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Gravimetría</s0>
<s5>07</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Spectrométrie UV</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Ultraviolet spectrometry</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Espectrometría UV</s0>
<s5>08</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Spectrométrie IR</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Infrared spectrometry</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Espectrometría IR</s0>
<s5>09</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Spectrométrie RMN</s0>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>NMR spectrometry</s0>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Espectrometría RMN</s0>
<s5>10</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Corrélation hétéronucléaire</s0>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Heteronuclear correlation</s0>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Correlación heteronuclear</s0>
<s5>11</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Composé cage</s0>
<s5>12</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Cage compound</s0>
<s5>12</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Compuesto jaula</s0>
<s5>12</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Orthoester</s0>
<s5>13</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Orthoester</s0>
<s5>13</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Ortoester</s0>
<s5>13</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE"><s0>Hétérocycle azote</s0>
<s5>14</s5>
</fC03>
<fC03 i1="14" i2="X" l="ENG"><s0>Nitrogen heterocycle</s0>
<s5>14</s5>
</fC03>
<fC03 i1="14" i2="X" l="SPA"><s0>Heterociclo nitrógeno</s0>
<s5>14</s5>
</fC03>
<fC03 i1="15" i2="X" l="FRE"><s0>Protéomique</s0>
<s5>15</s5>
</fC03>
<fC03 i1="15" i2="X" l="ENG"><s0>Proteomics</s0>
<s5>15</s5>
</fC03>
<fC03 i1="15" i2="X" l="SPA"><s0>Proteómica</s0>
<s5>15</s5>
</fC03>
<fC03 i1="16" i2="X" l="FRE"><s0>Réplication</s0>
<s5>16</s5>
</fC03>
<fC03 i1="16" i2="X" l="ENG"><s0>Replication</s0>
<s5>16</s5>
</fC03>
<fC03 i1="16" i2="X" l="SPA"><s0>Replicación</s0>
<s5>16</s5>
</fC03>
<fC03 i1="17" i2="X" l="FRE"><s0>Virus syndrome respiratoire aigu sévère</s0>
<s2>NW</s2>
<s5>17</s5>
</fC03>
<fC03 i1="17" i2="X" l="ENG"><s0>Severe acute respiratory syndrome virus</s0>
<s2>NW</s2>
<s5>17</s5>
</fC03>
<fC03 i1="17" i2="X" l="SPA"><s0>Severe acute respiratory syndrome virus</s0>
<s2>NW</s2>
<s5>17</s5>
</fC03>
<fC03 i1="18" i2="X" l="FRE"><s0>Bananine</s0>
<s2>NK</s2>
<s4>INC</s4>
<s5>76</s5>
</fC03>
<fC03 i1="19" i2="X" l="FRE"><s0>2,8,9-Trioxaadamantane-3,5,7-triol dérivé</s0>
<s2>NK</s2>
<s4>INC</s4>
<s5>77</s5>
</fC03>
<fC03 i1="20" i2="X" l="FRE"><s0>Prismane dérivé</s0>
<s2>NK</s2>
<s4>INC</s4>
<s5>78</s5>
</fC03>
<fC03 i1="21" i2="X" l="FRE"><s0>Indolo[2,3-b]quinoxaline dérivé</s0>
<s2>NK</s2>
<s4>INC</s4>
<s5>79</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Virose</s0>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Viral disease</s0>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Virosis</s0>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Infection</s0>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Infection</s0>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Infección</s0>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Coronavirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Coronavirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Coronavirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Appareil respiratoire pathologie</s0>
<s5>53</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Respiratory disease</s0>
<s5>53</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Aparato respiratorio patología</s0>
<s5>53</s5>
</fC07>
<fN21><s1>346</s1>
</fN21>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000414 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000414 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:05-0492308
   |texte=   Synthesis of novel test compounds for antiviral chemotherapy of severe acute respiratory syndrome (SARS)
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

Synthesis of novel test compounds for antiviral chemotherapy of severe acute respiratory syndrome (SARS)

Synthesis of novel test compounds for antiviral chemotherapy of severe acute respiratory syndrome (SARS)

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri